Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks.
Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtulowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Schindel F, Craig TJ. Bernstein JA, et al. Among authors: moldovan d. Ann Allergy Asthma Immunol. 2010 Aug;105(2):149-54. doi: 10.1016/j.anai.2010.06.005. Ann Allergy Asthma Immunol. 2010. PMID: 20674826 Clinical Trial.
Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity.
Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtułowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Craig TJ. Bernstein JA, et al. Among authors: moldovan d. Allergy Asthma Proc. 2011 Jan-Feb;32(1):36-42. doi: 10.2500/aap.2011.32.3404. Allergy Asthma Proc. 2011. PMID: 21262096
Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A. Lumry WR, et al. Among authors: moldovan d. Ann Allergy Asthma Immunol. 2011 Dec;107(6):529-37. doi: 10.1016/j.anai.2011.08.015. Epub 2011 Oct 5. Ann Allergy Asthma Immunol. 2011. PMID: 22123383 Clinical Trial.
Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial.
Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D, Farkas H, Levy R, Baker J, Hardiman Y, Totoritis MC, Relan A, Cicardi M; Study 1310 Investigators. Riedl MA, et al. Among authors: moldovan d. Ann Allergy Asthma Immunol. 2014 Feb;112(2):163-169.e1. doi: 10.1016/j.anai.2013.12.004. Epub 2014 Jan 7. Ann Allergy Asthma Immunol. 2014. PMID: 24468257 Clinical Trial.
Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor.
Farkas H, Varga L, Moldovan D, Obtulowicz K, Shirov T, Machnig T, Feuersenger H, Edelman J, Williams-Herman D, Rojavin M. Farkas H, et al. Among authors: moldovan d. Ann Allergy Asthma Immunol. 2016 Nov;117(5):508-513. doi: 10.1016/j.anai.2016.08.025. Epub 2016 Oct 24. Ann Allergy Asthma Immunol. 2016. PMID: 27788880 Free article. Clinical Trial.
Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
Reshef A, Grivcheva-Panovska V, Kessel A, Kivity S, Klimaszewska-Rembiasz M, Moldovan D, Farkas H, Gutova V, Fritz S, Relan A, Giannetti B, Magerl M. Reshef A, et al. Among authors: moldovan d. Pediatr Allergy Immunol. 2019 Aug;30(5):562-568. doi: 10.1111/pai.13065. Epub 2019 May 29. Pediatr Allergy Immunol. 2019. PMID: 30993784 Free PMC article. Clinical Trial.
153 results